Лекарственно-индуцированный аутоиммунный гепатит
- Авторы: Остроумова О.Д1, Филиппова А.В1, Кочетков А.И1
-
Учреждения:
- Российская медицинская академия непрерывного профессионального образования
- Выпуск: Том 28, № 2 (2021)
- Страницы: 43-53
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/313079
- DOI: https://doi.org/10.18565/pharmateca.2021.2.43-53
- ID: 313079
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
О. Д Остроумова
Российская медицинская академия непрерывного профессионального образования
Email: ostroumova.olga@mail.ru
д.м.н., профессор, зав. кафедрой терапии и полиморбидной патологии, Российская медицинская академия непрерывного профессионального образования; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней, Первый Московский государственный медицинский университет им. И.М. Сеченова Москва, Россия
А. В Филиппова
Российская медицинская академия непрерывного профессионального образованияМосква, Россия
А. И Кочетков
Российская медицинская академия непрерывного профессионального образованияМосква, Россия
Список литературы
- Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. September4, 2020. URL: https://www.ncbi.nlm.nih.gov/ books/NBK548188/
- Ghabril M, Fontana R., Rockey D., et al. Drug-induced liver injury caused by intravenouslyadministered medications: the Drug-Induced Liver Injury Network experience. Gastroenterol. 2013;47(6):553-58. doi: 10.1097/MCG.0b013e318276bf00.
- Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14(44):6774-85. doi: 10.3748/wjg.14.6774.
- Lewis J.H., Kleiner D.E. Hepatic injury due to drugs, herbal compounds, chemicals and toxins. In: Burt A.D., Portmann B.C., Ferrell L.D., editors. MacSween's pathology of the liver. 6th edition. Edinburgh (United Kingdom): Churchill Livingstone Elsevier; 2012:645-760.
- Bjornsson E.S., Hoofnagle J.H. Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports. Hepatology. 2016;63(2):590-603. doi: 10.1002/hep.28323.
- Буеверов А.О., Буеверова Е.Л.Лекарственно-индуцированный аутоиммунный гепатит: редкая болезнь или редкий диагноз? Доказательная гастроэнтерология. 2017; 6(1):47-55.
- Girard J.P, Haenni B., Bergoz R. Lupoid hepatitis following administration of penicillin. Case report and immunological studies. Helv Med Acta. 1967;34(1):23-35.
- Russell R.I., Allan J.G., Patrick R. Active chronic hepatitis after chlorpromazine ingestion. Br Med J. 1973;1(5854):655-56. Doi: 10.1136/ bmj.1.5854.655.
- Zhao S.X., Zhang Y.G., Tan P.F., et al. Clinical features of drug-induced autoimmune hepatitis and drug-induced liver injury: a comparative analysis. Chinese J Hepatology. 2016;24(4):302-6. Doi: 10.3760/ cma.j.issn.1007-3418.2016.04.012.
- Stine J.G., Northup P.G. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol. 2016;12(11):1291-1301. doi: 10.1080/17425255.2016.1211110
- Bjornsson E., Talwalkar J., Treeprasertsuk S., et al. Druginducedautoimmune hepatitis: clinical characteristics andprognosis. Hepatology. 2010;51(6):2040-2048. Doi: 10.1002/ hep.23588
- Heurgue A., Bernard-Chabert B., Diebold M., Andrade R.J. Drug-induced autoimmune hepatitis: a frequentdisorder. Gut. 2007;56(SupplIII):A271.
- Zapata E., Castiella A., Otazua P Hepatitis autoinmuneenGipuzkoa, Pais Vasco: epidemiologia, indices diagnosticose impacto de la edaden la histologia. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 2011; 103(Suppl I):137-38.
- Licata A., Maida M., Cabibi D. Clinical features and outcomes of patients with drug-inducedautoimmune hepatitis. National Center for Biotechnology Information. 2012;44(12):1116-20. doi: 10.1016/j.dld.2014.08.040.
- Yeong T.T., Lim K.H., Goubet S., et al. Natural history and outcomes in drug-induced autoimmune hepatitis. Hepatol Res. 2016;46(3):79-88. doi: 10.1111/hepr.12532.
- Cheng R., Cooper A., Kench J., et al. Ipilimumab-induced toxicities and the gastroenterologist. Gastroenterol Hepatol. 2015;30(4):657-66. doi: 10.1111/jgh.12888.
- Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].September 5, 2020.https://www.ncbi.nlm.nih.gov/books/ NBK548720/
- Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. September 7, 2020. URL: https://www.ncbi.nlm.nih.gov/ books/NBK548236/
- Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. September 13, 2020. URL: https://www.ncbi.nlm.nih.gov/ books/NBK547953/
- Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. September 13, 2020. URL: https://www.ncbi.nlm.nih.gov/ books/NBK548671/
- Etxagibel A., Julia M.R., Brotons A., et al. Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. Med Case Reports. 2008;2(1):25. doi: 10.1186/1752- Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов. Conflict of interests. The authors declare no conflicts of interest. 1947-2-25.
- Charier F, Chagneau-Derrode C., Levillain P, et al. Glivec induced autoimmune hepatitis. Gastroenterol Clin Biol. 2009;33(10-11):982-84. doi: 10.1016/j.gcb.2009.07.034
- Primo J., Michavila J., Jimenez I. Efalizumab-induced autoimmune hepatitis. Gastroenterol Hepatol. 2010;33(1):69-70. Doi: 10.1016/j. gastrohep.2009.07.005.
- Adar T., Mizrahi M., Pappo O., et al. Adalimumab-induced autoimmune hepatitis. Clin Gastroenterol. 2010;44(1):20-2. Doi: 10.1097/ MCG.0b013e3181a745e7.
- Humayun F, Shehab T.M., Tworek J.A., Robert J.F. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. Med Case Reports. 2007;1(1):88. doi: 10.1186/1752-1947-1-88.
- Harada K., Akai Y, Koyama S., et al. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol. 2008;27(8):1063-66. doi: 10.1007/s10067-008-0885-1.
- Fathalla B.M., Goldsmith D.P, Pascasio J.M., Alan Baldridge. Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept. Clin Rheumatol. 2008;14(5):297-98. Doi: 10.1097/ RHU.0b013e318188b1df.
- Cueto R., Valdivieso P, Lucena M.I., et al. Statins: hepatic disease and hepatotoxicity risk. Open Gastroenterol. 2008;2(1):18-23. doi: 10.2174/1874259900802010018
- de Denus S., Spinler S.A., Miller K., Peterson A.M. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24(5):584-91. doi: 10.1592/phco.24.6.584.34738.
- Cravo M., Silva R., Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. BioDrugs. 2010;24(1):25-7. doi: 10.2165/11586210-000000000-00000.
- Carlsen K.M., Riis L., Madsen O.R. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009;28(8):1001-3. doi: 10.1007/s10067-009-1179-y.
- Khanna M., Shirodkar M.A., Gottlieb A.B. Etanercept therapy in patients with autoimmunity and hepatitis C. Dermatolog Treat. 2003;14(4):229-32. doi: 10.1080/09546630310020470.
- Goldenberg G., Jorizzo J.L. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. Dermatolog Treat. 2005;16(5-6):347-49. doi: 10.1080/09546630500424722.
- Kleiner D.E., Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57(8):2233-40. doi: 10.1007/s10620-012-2140-5.
- Efe C. Drug induced autoimmune hepatitis and TNF-а blocking agents: is there a real relationship? Autoimmun Rev. 2013;12(3):337-39. doi: 10.1016/j.autrev.2012.03.010.
- Ghabril M, Bonkovsky H.L., Kum C., et al. Liver injury from tumor necrosis factor-а antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558-64. Doi: 10.1016/j. cgh.2012.12.025.
- Garcfa-Cortes M., Borraz Y, Lucena M.I., et al. Liver injury induced by «natural remedies»: an analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev EspEnferm Dig. 2008;100(11):688-95. doi: 10.4321/s1130-01082008001100004.
- Sanchez M., Castiella A., Zapata E., et al. Autoimmune Hepatitis (Immune-Mediated Liver Injury) Induced By Rosuvastatin. Gastroenterologfa y Hepatologfa. 2018;41(5):311-13. doi: 10.1016/j.gastrohep.2017.05.010.
- Primo J, Michavila J., Jimenez I. Efalizumab-induced autoimmune hepatitis. Gastroenterol Hepatol. 2010;33(1):69-70. Doi: 10.1016/j. gastrohep.2009.07.005.
- Uppsala Monitoring Centre. [Internet]. September15,2020.http://www.vigiaccess.org/
- de la Torre-Alaez M., Inarrairaegui M. Drug Liver Injury Induced by Olmesartan Mediated by Autoimmune-Like Mechanism: A Case Report. Eur J Case Rep Intern Med.2020;7(1):1407. doi: 10.12890/2020_001407.
- Klapko O, Ghoulam E., Jakate S., Eswaran S.,Usha L.Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy. Anticancer Res. 2017;37(8):4173-76. doi: 10.21873/anticanres.11805.
- Castiella A, Zapata E., Isabel L.M., Andrade R. J. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol. 2014;6(4):160-68. doi: 10.4254/wjh.v6.i4.160.
- Liu Z.X., Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755-74. doi: 10.1016/s1089-3261(02)00025-9.
- Suzuki A., Brunt E.M., Kleiner D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury Hepatology 2011;54(3):931-39. doi: 10.1002/hep.24481.
- Bjornsson E., Talwalkar J., Treeprasertsuk S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040-48. Doi: 10.1002/ hep.23588.
- Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958-76. doi: 10.1007/s10620-011-1611-4.
- Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. Clin Pathol. 2009;62(6):481-92. Doi: 10.1136/ jcp.2008.058248.
- Appleyard S., Saraswati R., Gorard D.A. Autoimmune hepatitis triggered by nitrofurantoin: a case series. Med Case Rep. 2010;4(1):311. doi: 10.1186/1752-1947-4-311.
- Castiella A., Zapata E., Lucena E. Hepatotoxicity with autoimmune features. Analysis of the cases included in the Spanish Dili registry. Basic Clin Pharmacol Toxicol. 2011;109(3):53.
- Ju H.Y., Jang J.Y, Jeong S.W., et al. The clinical features of drug-induced liver injury observed through liver biopsy: focus on relevancy to autoimmune hepatitis. Clin Mol Hepatol. 2012;18(2):213-18. Doi: 10.3350/ cmh.2012.18.2.213.
- Iorga A., Dara L., Kaplowitz N. Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis. Int J Molecular Sci. 2017;18(5):1018. Doi: 10.3390/ ijms18051018.
- Vento S., Guella L., Mirandola F., et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet. 1995;346(8975):608-9. doi: 10.1016/s0140-6736(95)91438-2.
- Sugimoto K., Ito T, Yamamoto N., Shiraki K. Seven cases of autoimmune hepatitis that developed after drug-induced liver injury. Hepatology. 2011;54(5):1892-93. Doi: 10.1002/ hep.24513.
- Manns M.P, Czaja A.J., Gorham J.D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-213. doi: 10.1002/hep.23584.
- Chalasani N., Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246-59. doi: 10.1053/j.gastro.2010.04.001.
- Остроумова О.Д., Борисова Е.В., Пиксина Г.Ф., Павлеева Е.Е. Лекарственные поражения печени в практике врача первичного звена (обзор клинических рекомендаций). Медицинский алфавит. 2020;21:58-69.
- Czaja A. J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56;(4):958-76. doi: 10.1007/s10620-011-1611-4.
- Lucena M.I, Kaplowitz N., Hallal H., et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55(4):820-27. Doi: 10.1016/j. jhep.2010.12.041.
- Larrey D., Pageaux G.P Genetic predisposition to drug-induced hepatotoxicity. J Hepatol. 1997;26;(2):12-21. doi: 10.1016/s0168-8278(97)80492-8.
- Bjornsson E.S., Gunnarsson B.I., Grondal G. Risk of drug-inducedliver injury from tumor necrosis factor antagonists. ClinGastroenterol Hepatol.2015;13(3):602-8. Doi: 10.1016/j. cgh.2014.07.062.
- Chabril M,. Bonkovsky H.L., Kum C. Liver injury from tumornecrosis factor-а antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558-64. Doi: 10.1016/j. cgh.2012.12.025.
- Liver Tox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. September6, 2020. URL: http://livertox.nlm.nih.gov/
- Chabril M., Bonkovsky H.L., Kum C. Liver injury from tumor necrosis factor-а antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558-64. Doi: 10.1016/j. cgh.2012.12.025
- Li C.M., Zhang J.Y, Tang Y.Y., Mao Y.M. Research advances in drug-induced autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi. 2016;24(11):874-76. doi: 10.3760/cma.j.is sn.1007-3418.2016.11.016.
- deLemos A.S., Foureau D.M., Jackobs C. Drug-induced liver injurywith autoimmune features. Semin Liver Dis. 2014;34(2):194-204. doi: 10.1055/s-0034-1375959.
- Stine J.G., Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol. 2016;12(11):1291-1301. doi: 10.1080/17425255.2016.1211110.
- Weiler-Normann C., Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55(4):747-49. doi: 10.1016/j.jhep.2011.02.024.
- Tisdale J.E., Miller D.A. Drug Induced Diseases: Prevention, Detection, and Management. American Society of Health-System Pharmacists. 2018;1399. PMCID: PMC1805477
- Naranjo C.A., Busto U., Sellers E.M, et al. A metod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. doi: 10.1038/clpt.1981.154.
- Сычев Д.А., Остроумова О.Д., Переверзев А.П. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020;27(6):113-26.
- Licata A., Butera G., Macaluso F.S., et al.Clinical features and outcomes of patients with drug-induced autoimmune hepatitis. Dig Liver Dis.2014;46(12):1116-20. Doi: 10.1016/j. dld.2014.08.040.
- Torisu Y, Nakano M., Takano K., et al. Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. World J Hepatol. 2017;9(1):57-63. doi: 10.4254/wjh. v9.i1.57
- Miyake Y, Iwasaki Y, Kobashi H., et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int. 2009;3(4):556-62. doi: 10.1007/s12072-009-9155-9.
Дополнительные файлы
![](/img/style/loading.gif)